Trial reportDementia and geriatric cognitive disorders2017
Effectiveness of Florbetapir PET Imaging in Changing Patient Management.
Trial report in Dementia and geriatric cognitive disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03507257 (Longitudinal Early-onset Alzheimer's Disease Study Protocol), which is not on this map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Longitudinal Early-onset Alzheimer's Disease Study Protocol
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2018Pooled it
- Development and Implementation of a Radiation Safety Screening Protocol for a Clinical Study Using Amyloid Positron Emission Tomography Imaging.Ochsner journal · 2026Article
- A brief history of Aβ imaging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use.The journal of prevention of Alzheimer's disease · 2025Review
- Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Clinical Utility of an Alzheimer's Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study.Diagnostics (Basel, Switzerland) · 2025Article
- Plasma biomarkers increase diagnostic confidence in patients with Alzheimer's disease or frontotemporal lobar degeneration.Alzheimer's research & therapy · 2024Article
- A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment.Annals of clinical and translational neurology · 2023Article
- Software compatibility analysis for quantitative measures of [EJNMMI research · 2023Article
- Clinical impact of amyloid PET usingAnnals of nuclear medicine · 2022Article
- Quantification of amyloid PET for future clinical use: a state-of-the-art review.European journal of nuclear medicine and molecular imaging · 2022Review
- The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Review
- Impact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinic.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- Clinical Impact of PET WithFrontiers in neurology · 2021Article
- Relationship between comprehensive geriatric assessment and amyloid PET in older persons with MCI.BMC geriatrics · 2020Article
- Initial Physician Experience with [Journal of Alzheimer's disease reports · 2020Article
- Peripheral Biomarkers for Alzheimer's Disease: Update and Progress.Neurology and therapy · 2019Article
- The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes.Brain : a journal of neurology · 2019Article
- Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria.Medicine · 2019Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo evaluate the impact of amyloid PET imaging on diagnosis and patient management in a multicenter, randomized, controlled study.
methodsPhysicians identified patients seeking a diagnosis for mild cognitive impairment or dementia, possibly due to Alzheimer disease (AD), and recorded a working diagnosis and a management plan. The patients underwent florbetapir PET scanning and were randomized to either immediate or delayed (1-year) feedback regarding amyloid status. At the 3-month visit, the physician updated the diagnosis and recorded a summary of the actual patient management since the post-scan visit. The study examined the impact of immediate versus delayed feedback on patient diagnosis/management at 3 and 12 months.
resultsA total of 618 subjects were randomized (1:1) to immediate or delayed feedback arms, and 602 subjects completed the 3-month primary endpoint visit. A higher proportion of patients in the immediate feedback arm showed a change in diagnosis compared to the controls (32.6 vs. 6.4%; p = 0.0001). Similarly, a higher proportion of patients receiving immediate feedback had a change in management plan (68 vs. 55.5%; p < 0.002), mainly driven by changes in AD medication. Specifically, acetylcholinesterase inhibitors were prescribed to 67% of the amyloid-positive and 27% of the amyloid-negative subjects in the information group compared with 56 and 43%, respectively, in the control group (p < 0.0001). These between-group differences persisted until the 12-month visit.
conclusionKnowledge of the amyloid status affects the diagnosis and alters patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.